8-hydroxy-7-iodo-5-quinolinesulfonic acid profile

8-hydroxy-7-iodo-5-quinolinesulfonic acid: used with iodine isotopes in radioisotope scanning; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	11043
CHEMBL ID	1788402
CHEBI ID	135481
SCHEMBL ID	94250
MeSH ID	M0043601

Synonym
nsc 3784
7-iodo-5-sulfonic acid-8-hydroxyquinoline
8-hydroxy-7-iod-5-chinolinsulfonsaeure
c9h6ino4s
5-sulfo-7-iodo-8-quinolinol
5-iodo-8-quinolinol-5-sulfonic acid
brn 0223832
5-sulfo-7-iodo-8-hydroxyquinoline
8-hydroxy-7-iodoquinoline-5-sulphonic acid
7-iodooxine-5-sulfonic acid
7-iodo-8-hydroxylquinoline-5-sulfonic acid
8-hydroxy-7-iodo-5-quinolinesulfonic acid
einecs 208-938-4
jod-hydroxychinolin-sulfonsaeure
6e8y02xfei ,
unii-6e8y02xfei
7-iodo-8-hydroxyquinoline-5-sulfonic acid
yatren
5-quinolinesulfonic acid, 8-hydroxy-7-iodo-
anayodin
wln: t66 bnj gswq ii jq
ferron (analytical reagent)
yellon
ferron
8-hydroxy-7-iodoquinolinesulfonic acid
547-91-1
8-hydroxy-7-iodoquinoline sulfonate
chiniofon
sefona
nsc3784
loretin
meditrene
quiniophen
quinoxyl
nsc-3784
8-hydroxy-7-iodo-5-quinoline sulfonic acid
8-hydroxy-7-iodoquinoline-5-sulfonic acid
STK371235
NCGC00160410-01
SR-01000634736-1
CHEBI:135481
H0254
BBL002814
tox21_111795
cas-547-91-1
dtxcid9026136
dtxsid1046136 ,
m-iodo-o-hydroxyquinolineanasulfonic acid
8-hydroxy-7-iodo-quinoline-5-sulfonic acid;7-iodo-8-hydroxyquinoline-5-sulfonic acid
A830370
smr001812723
MLS004774009
CCG-44937
AKOS005203037
FT-0632363
CHEMBL1788402
SCHEMBL94250
tox21_111795_1
NCGC00160410-02
8-hydroxy-7-iodo-5-quinioline sulfonic acid [who-dd]
8-hydroxy-7-iodo-5-quinolinesulfonic acid [mi]
8-hydroxy-7-iodo-quinoline-5-sulfonic acid
mfcd00006793
cambridge id 5192841
DS-1838
8-hydroxy-7-iodo-5-quinolinesulfonic acid, for spectrophotometric det. of fe(iii), >=98.5%
Q5101067
quiniofon; sefona; sodium chiniofon; yatren; yochinol
BRD-K52284881-236-01-6
O11676
2-amino-1-morpholin-4-yl-ethanonehcl
CS-0155825
8-hydroxy-7-iodoquinoline-5-sulfonicacid
HY-W103183

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" A high content of Al(30) nanoclusters in PACl improves the removal efficiency over broader dosage and pH range."	( Polyaluminum chloride with high Al30 content as removal agent for arsenic-contaminated well water. Casentini, B; Furrer, G; Masion, A; Mertens, J; Pöthig, R; Wehrli, B, 2012)	0.38
"Ferron dosage ([Ferron]) is key to ferron-timed spectrophotometry (ferron assay)."	( An important improvement in Ferron-timed spectrophotometry. Chang, F; Ren, Y; Shi, Q; Zhang, J, 2013)	0.39

Class	Description
hydroxyquinoline
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Luciferase	Photinus pyralis (common eastern firefly)	Potency	5.7255	0.0072	15.7588	89.3584	AID624030
phosphopantetheinyl transferase	Bacillus subtilis	Potency	2.5119	0.1413	37.9142	100.0000	AID1490
GLS protein	Homo sapiens (human)	Potency	28.1838	0.3548	7.9355	39.8107	AID624170
TDP1 protein	Homo sapiens (human)	Potency	21.1360	0.0008	11.3822	44.6684	AID686978; AID686979
hypothetical protein, conserved	Trypanosoma brucei	Potency	50.1187	0.2239	11.2451	35.4813	AID624173
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	2.7540	0.0123	7.9835	43.2770	AID1645841
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	3.5481	0.0355	20.9770	89.1251	AID504332
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	11.8832	0.0007	23.0674	1,258.9301	AID743085
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	24.6554	0.0391	47.5451	146.8240	AID1224845
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	39.8107	0.3548	28.0659	89.1251	AID504847
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	3.3489	0.0006	27.2152	1,122.0200	AID743202; AID743219
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	12.5893	0.0079	8.2332	1,122.0200	AID2551
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	5.6234	0.2512	15.8432	39.8107	AID504327
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	31.6228	0.0601	10.7453	37.9330	AID492961
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Catechol O-methyltransferase	Rattus norvegicus (Norway rat)	IC50 (µMol)	7.0795	0.0022	2.8127	7.0795	AID1149251
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159537	qHTS screening for TAG (triacylglycerol) accumulators in algae	2017	Plant physiology, Aug, Volume: 174, Issue:4	Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID1149251	Inhibition of Sprague-Dawley rat liver COMT after 10 mins using 0.05 uCi [14CH3]-SAM as substrate	1976	Journal of medicinal chemistry, Apr, Volume: 19, Issue:4	Catechol O-methyltransferase. 8. Structure-activity relationships for inhibtion by 8-hydroxyquinolines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	3 (11.11)	18.7374
1990's	1 (3.70)	18.2507
2000's	5 (18.52)	29.6817
2010's	11 (40.74)	24.3611
2020's	7 (25.93)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	1 (3.70%)	4.05%
Observational	0 (0.00%)	0.25%
Other	26 (96.30%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
levoplast Levoplast: mixture of acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R,R))-, castor oil, celluloidin, collodion & tannins	2.15	1	C-nitro compound
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	2.06	1	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
hippuric acid hippuric acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #4591. N-benzoylglycine : An N-acylglycine in which the acyl group is specified as benzoyl.	2.15	1	N-acylglycine	human blood serum metabolite; uremic toxin
phosphoric acid phosphoric acid: concise etchant is 37% H3PO4. phosphoric acid : A phosphorus oxoacid that consists of one oxo and three hydroxy groups joined covalently to a central phosphorus atom.	2	1	phosphoric acids	algal metabolite; fertilizer; human metabolite; NMR chemical shift reference compound; solvent
xanthine 7H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-7 is protonated.. 9H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-9 is protonated.	2.15	1	xanthine	Saccharomyces cerevisiae metabolite
atrolactic acid atrolactic acid: see also 3-isomer; RN given refers to parent cpd without isomeric designation; structure	2.15	1	2-hydroxy monocarboxylic acid
etofylline etofylline: etophyllin appeared once in PubMed: Wien Med Wochenschr. 1986 May 15;136(9):213-8 as a combination drug with theophylline (spelt without e, theophllin)	2.15	1	oxopurine
oxyquinoline Oxyquinoline: An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics.. quinolin-8-ol : A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 8. Its fungicidal properties are used for the control of grey mould on vines and tomatoes.	1.95	1	monohydroxyquinoline	antibacterial agent; antifungal agrochemical; antiseptic drug; iron chelator
n-acetyltryptophan N-acetyltryptophan : An N-acetylamino acid that is the N-acetyl derivative of tryptophan.	2.15	1	N-acetyl-amino acid; tryptophan derivative	metabolite
ethacridine Ethacridine: A topically applied anti-infective agent.	2.15	1	acridines
altretamine Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.	2.15	1	triamino-1,3,5-triazine
2,5-di-tert-butylhydroquinone 2,5-di-tert-butylbenzene-1,4-diol : A member of the class of hydroquinones that is benzene-1,4-diol substituted by tert-butyl groups at position 2 and 5.	2.15	1	hydroquinones
broxyquinoline broxyquinoline: structure	1.95	1	organohalogen compound; quinolines
clioquinol Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.. 5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.	1.95	1	monohydroxyquinoline; organochlorine compound; organoiodine compound	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; antiprotozoal drug; chelator; copper chelator
cloxyquin cloxyquin: has antitubercular activity; structure in first source	1.95	1	organochlorine compound; quinolines
cx546 1-(1,4-benzodioxan-6-ylcarbonyl)piperidine: structure in first source	2.15	1
diphenhydramine Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.	2.15	1	ether; tertiary amino compound	anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative
diuron Diuron: A pre-emergent herbicide.. diuron : A member of the class of 3-(3,4-substituted-phenyl)-1,1-dimethylureas that is urea in which both of the hydrogens attached to one nitrogen are substituted by methyl groups, and one of the hydrogens attached to the other nitrogen is substituted by a 3,4-dichlorophenyl group.	2.15	1	3-(3,4-substituted-phenyl)-1,1-dimethylurea; dichlorobenzene	environmental contaminant; mitochondrial respiratory-chain inhibitor; photosystem-II inhibitor; urea herbicide; xenobiotic
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	2.15	1	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
iodoquinol Iodoquinol: One of the halogenated 8-quinolinols widely used as an intestinal antiseptic, especially as an antiamebic agent. It is also used topically in other infections and may cause CNS and eye damage. It is known by very many similar trade names world-wide.. iodoquinol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by iodine. It is considered the drug of choice for treating asymptomatic or moderate forms of amoebiasis.	1.95	1	monohydroxyquinoline; organoiodine compound	antiamoebic agent; antibacterial agent; antiprotozoal drug; antiseptic drug
ipriflavone ipriflavone : A member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women.	2.15	1	aromatic ether; isoflavones	bone density conservation agent
mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.	2.15	1	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator
nocodazole [no description available]	2.15	1	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	1.95	1	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
piribedil Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.	2.15	1	N-arylpiperazine
procainamide Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.	2.15	1	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
prometone prometone: structure. prometon : A methoxy-1,3,5-triazine that is 6-methoxy-1,3,5-triazine-2,4-diamine in which the one of the hydrogens of each amino group is substituted by an isopropyl group.	2.15	1	diamino-1,3,5-triazine; methoxy-1,3,5-triazine	environmental contaminant; herbicide; xenobiotic
propanil Propanil: A chlorinated anilide that is used as an herbicide.. propanil : An anilide resulting from the formal condensation of the carboxy group of propanoic acid with the amino group of 3,4-dichloroaniline. It is a herbicide used for the treatment of numerous grasses and broad-leaved weeds in rice, potatoes, and wheat.	2.15	1	anilide; dichlorobenzene	herbicide
sulfadimethoxine Sulfadimethoxine: A sulfanilamide that is used as an anti-infective agent.. sulfadimethoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 2- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position.	2.15	1	aromatic ether; pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; drug allergen; environmental contaminant; xenobiotic
sulfamethazine Sulfamethazine: A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.. sulfamethazine : A sulfonamide consisting of pyrimidine with methyl substituents at the 4- and 6-positions and a 4-aminobenzenesulfonamido group at the 2-position.	2.15	1	pyrimidines; sulfonamide antibiotic; sulfonamide	antibacterial drug; antiinfective agent; antimicrobial agent; carcinogenic agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; ligand; xenobiotic
sulfathiazole Sulfathiazole: A sulfathiazole compound that is used as a short-acting anti-infective agent. It is no longer commonly used systemically due to its toxicity, but may still be applied topically in combination with other drugs for the treatment of vaginal and skin infections, and is still used in veterinary medicine.. sulfathiazole : A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position.	2.15	1	1,3-thiazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
testosterone [no description available]	2.15	1	3-hydroxy steroid	androgen
2-hydroxybenzylbenzimidazole 2-hydroxybenzylbenzimidazole: RN given refers to cpd without isomeric designation	2.15	1
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	1.95	1	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
etimizol Etimizol: A xanthine-related, putative nootropic drug.	2.15	1
egtazic acid Egtazic Acid: A chelating agent relatively more specific for calcium and less toxic than EDETIC ACID.. ethylene glycol bis(2-aminoethyl)tetraacetic acid : A diether that is ethylene glycol in which the hydrogens of the hydroxy groups have been replaced by 2-[bis(carboxymethyl)amino]ethyl group respectively.	1.95	1	diether; tertiary amino compound; tetracarboxylic acid	chelator
nifenalol nifenalol: adrenergic beta-blocker with good antiarrhythmic properties; also tends to lower blood pressure & provide protection against angina; minor descriptor (75-86); on-line & INDEX MEDICUS search ETHANOLAMINES (75-86); RN given refers to parent cpd without isomeric designation	2.15	1	C-nitro compound
bis(4-hydroxyphenyl)sulfone bis(4-hydroxyphenyl)sulfone: structure and RN in first source. 4,4'-sulfonyldiphenol : A sulfone that is diphenyl sulfone in which both of the para hydrogens have been replaced by hydroxy groups.	2.15	1	bisphenol; sulfone	endocrine disruptor; metabolite
8-hydroxyquinoline-5-sulfonic acid 8-hydroxyquinoline-5-sulfonic acid: RN given refers to parent cpd	2.39	2
salicylanilide salicylanilide: RN given refers to parent cpd. salicylanilide : An amide of salicylic acid and of aniline; it is therefore both a salicylamide and an anilide.	2.15	1	benzanilide fungicide; salicylamides; salicylanilides
2-phenylbutyric acid 2-phenylbutyric acid : A monocarboxylic acid that is butyric acid substituted by a phenyl group at position 2.	2.15	1	benzenes; monocarboxylic acid	human xenobiotic metabolite
4,4'-dimethoxybenzophenone 4,4'-dimethoxybenzophenone: structure in first source	2.15	1
6-phenyl-1,3,5-triazine-2,4-diamine 6-phenyl-1,3,5-triazine-2,4-diamine: structure in first source	2.15	1
quinaldic acid [no description available]	2.15	1	quinolinemonocarboxylic acid	human metabolite; Saccharomyces cerevisiae metabolite
N-(2-methoxyphenyl)acetamide [no description available]	2.15	1	acetamides; methoxybenzenes
fast red b Fast Red B: structure in first source. fast red B : An organosulfonate salt composed from 2-methoxy-4-nitrobenzene-1-diazonium and 5-sulfonaphthalene-1-sulfonate in a 1:1 ratio. Used for demostrating enterochromaffin in carcinoid tumours.	2.15	1
methylenebis(chloroaniline) Methylenebis(chloroaniline): Aromatic diamine used in the plastics industry as curing agent for epoxy resins and urethane rubbers. It causes bladder, liver, lung, and other neoplasms.. 4,4'-methylene-bis-(2-chloroaniline) : A chloroaniline that consists of two 2-chloroaniline units joined by a methylene bridge.	2.15	1	chloroaniline	metabolite
di-(4-aminophenyl)ether di-(4-aminophenyl)ether: structure	2.15	1	aromatic ether
diphenylguanidine diphenylguanidine: vulcanization accelerator; RN given refers to parent cpd. 1,3-diphenylguanidine : Guanidine carrying a phenyl substituent on each of the two amino groups. It is used as an accelerator in the rubber industry.	2.15	1	guanidines	allergen
4-Anilino-4-oxobutanoic acid [no description available]	2.15	1	anilide
4-bromoaniline 4-bromoaniline: RN given refers to parent cpd; structure given in Merck Index, 9th ed, #1403	2.03	1
4-chloroaniline 4-chloroaniline: RN given refers to parent cpd; structure. 4-chloroaniline : A chloroaniline in which the chloro atom is para to the aniline amino group.	2.03	1	chloroaniline; monochlorobenzenes
mephobarbital Mephobarbital: A barbiturate that is metabolized to PHENOBARBITAL. It has been used for similar purposes, especially in EPILEPSY, but there is no evidence mephobarbital offers any advantage over PHENOBARBITAL.. mephobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by ethyl and phenyl groups.	2.15	1	barbiturates	anticonvulsant
etryptamine etryptamine: RN given refers to cpd without isomeric designation	2.15	1	indoles
sulfacetamide [no description available]	2.15	1
cinchophen cinchophen: was heading 1963-94; ACIPHENOCHINOLIUM was see CHINOPHEN 1978-94; use QUINOLINES to search CINCHOPHEN 1966-94	2.15	1	quinolines
2-aminobenzothiazole [no description available]	2.15	1	benzothiazoles
carzenide [no description available]	2.15	1	sulfonamide
nitrilotriacetic acid Nitrilotriacetic Acid: A derivative of acetic acid, N(CH2COOH)3. It is a complexing (sequestering) agent that forms stable complexes with Zn2+. (From Miall's Dictionary of Chemistry, 5th ed.)	2.15	1	NTA; tricarboxylic acid	carcinogenic agent; nephrotoxic agent
n-(2-cyanoethyl)-2-phenylethylamine N-(2-cyanoethyl)-2-phenylethylamine: prodrug of 2-phenylethylamine	2.15	1
cyclooctane [no description available]	2.15	1
triphenyltetrazolium chloride 2,3,5-triphenyltetrazolium chloride : An organic chloride salt having 2,3,5-triphenyltetrazolium as the counterion.	2.15	1	organic chloride salt	dye; indicator
2,7-diacetylaminofluorene 2,7-diacetylaminofluorene: has been found to induce leukemia in animals; minor descriptor (75-84); on-line search 2-ACETYLAMINOFLUORENE/AA (75-84); Index Medicus search 2-ACETYLAMINOFLUORENE/AA (80-82), FLUORENES (75-79)	2.15	1
3,4-pyridinedicarboxylic acid 3,4-pyridinedicarboxylic acid: structure in first source	2.15	1	pyridinedicarboxylic acid
4-(benzoylamino)-2-hydroxybenzoic acid 4-(benzoylamino)-2-hydroxybenzoic acid: Bepask is calcium salt	2.15	1	benzamides
tropic acid tropic acid: acid moiety of ester alkaloids hyoscyamine & scopolamine; RN given refers to parent cpd with unspecified isomeric designation; structure. tropic acid : A 3-hydroxy monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a phenyl group, and one of the methyl hydrogens is substituted by a hydroxy group.	2.15	1	3-hydroxy monocarboxylic acid	human xenobiotic metabolite
1-acetylisatin 1-acetylisatin: structure in first source	2.15	1	indoledione
4-cumylphenol [no description available]	2.15	1	diarylmethane
5-methylisatin 5-methylisatin: structure in first source	2.15	1
2-hydrazinobenzothiazole [no description available]	2.15	1
1,2,3-trimethoxybenzene 1,2,3-trimethoxybenzene : A methoxybenzene that is benzene substituted by methoxy groups at positions 1, 2 and 3 respectively.	2.15	1	methoxybenzenes	plant metabolite
2-amino-5-chlorobenzophenone 2-amino-5-chlorbenzophenone: structure given in first source	2.15	1
diphenamid diphenamid: do not confuse with anti-inflammatory agent difenpiramide; structure	2.15	1	diarylmethane
4-(4-nitrobenzyl)pyridine [no description available]	2.15	1
5-methyl-3-phenylisoxazole-4-carboxylic acid 5-methyl-3-phenylisoxazole-4-carboxylic acid: has anti-tumor, antiviral, hypoglycemic, antifungal and anti-HIV activities; structure in first source	2.15	1
2-acetylbenzofuran 2-acetylbenzofuran: structure in first source	2.15	1
pyrazon pyrazon: structure; do not confuse with phenazone which is a synonym to antipyrine. chloridazon : A pyridazinone that is pyridazin-3(2H)-one substituted by an amino group at position 5, a chloro group at position 4 and a phenyl group at position 2.	2.15	1	benzenes; organochlorine compound; primary amino compound; pyridazinone	environmental contaminant; herbicide; xenobiotic
2-amino-5-nitrobenzophenone 2-amino-5-nitrobenzophenone: urinary metabolite of nitrazepam	2.15	1
(4-tert-Butyl-phenoxy)-acetic acid [no description available]	2.15	1	monocarboxylic acid
lenacil lenacil: Russian drug. herbicide : A substance used to destroy plant pests.. lenacil : A cyclopentapyrimidine that is 6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione substituted by a cyclohexyl group at position 3.	2.15	1	cyclopentapyrimidine	agrochemical; environmental contaminant; herbicide; xenobiotic
chlordesmethyldiazepam [no description available]	2.15	1	benzodiazepine
2-amino-2',5-dichlorobenzophenone 2-amino-2',5-dichlorobenzophenone: structure given in first source	2.15	1
2-(2'-hydroxyphenyl)benzimidazole 2-(2'-hydroxyphenyl)benzimidazole: structure in first source	2.15	1
4-phthalimidobutyric acid 4-phthalimidobutyric acid: teratogen; RN given refers to parent cpd	2.15	1
azabutyrone azabutyrone: Russian drug; RN given refers to parent cpd; structure	2.15	1
2-(2-hydroxyphenyl)benzothiazole 2-(1,3-benzothiazol-2-yl)phenol : A member of the class of benzothiazoles that is 1,3-benzothiazole substituted by a 2-hydroxyphenyl group at position 2.	2.15	1	benzothiazoles; phenols	geroprotector
4,5-dichlorocatechol [no description available]	2.15	1
n-butylbenzenesulfonamide N-butylbenzenesulfonamide: a neurotoxic plasticising agent. N-butylbenzenesulfonamide : A sulfonamide that is benzenesulfonamide substituted by a butyl group at the nitrogen atom. It has been isolated from the plant Prunus africana and has been shown to exhibit antiandrogenic activity.	2.15	1	sulfonamide	neurotoxin; plant metabolite
3-phenoxybenzoic acid 3-phenoxybenzoic acid: metabolite associated with exposure to pyrethroid insecticides. 3-phenoxybenzoic acid : A phenoxybenzoic acid in which the phenoxy group is meta to the carboxy group. It is a metabolite of pyrethroid insecticides.	2.15	1	phenoxybenzoic acid	human xenobiotic metabolite; marine xenobiotic metabolite
nitroxoline nitroxoline: structure in Merck Index, 9th ed, #6475; RN given refers to parent cpd. nitroxoline : A monohydroxyquinoline in which the hydroxy group is positioned at C-8 with a nitro group trans to it at C-5.	1.95	1	C-nitro compound; monohydroxyquinoline	antifungal agent; antiinfective agent; antimicrobial agent; renal agent
2-(2-hydroxyethylmercapto)benzothiazole 2-(2-hydroxyethylmercapto)benzothiazole: reaction product of 2-mercaptobenzothiazole, well-known rubber vulcanization accelerator; structure in first source	2.15	1
carboxin Carboxin: A systemic agricultural fungicide and seed treatment agent.. carboxin : An anilide obtained by formal condensation of the amino group of aniline with the carboxy group of 2-methyl-5,6-dihydro-1,4-oxathiine-3-carboxylic acid. A fungicide for control of bunts and smuts that is normally used as a seed treatment.	2.15	1	anilide fungicide; anilide; enamide; organosulfur heterocyclic compound; oxacycle; secondary carboxamide	antifungal agrochemical; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor
meturin [no description available]	2.15	1
molybdenum Molybdenum: A metallic element with the atomic symbol Mo, atomic number 42, and atomic weight 95.95. It is an essential trace element, being a component of the enzymes xanthine oxidase, aldehyde oxidase, and nitrate reductase.	2	1	chromium group element atom	micronutrient
ferric chloride ferric chloride: RN given refers to cpd with MF of Fe-Cl3; used to induce experimental arterial thrombosis to evaluate antithrombotic agents	2.06	1	iron coordination entity	astringent; Lewis acid
2-bromo-N-phenylbenzamide [no description available]	2.15	1	benzamides
4-chlorohippuric acid 4-chlorohippuric acid: metabolite of zomepirac; RN given refers to parent cpd	2.15	1
4-chlorophenoxyacetic acid 4-chlorophenoxyacetic acid: RN given refers to parent cpd; structure. (4-chlorophenoxy)acetic acid : A chlorophenoxyacetic acid that is phenoxyacetic acid carrying a chloro substituent at position 4.	2.15	1	chlorophenoxyacetic acid; monochlorobenzenes	phenoxy herbicide
2,5-dichloro-1,4-phenylenediamine 2,5-dichloro-1,4-phenylenediamine: structure in first source	2.15	1
metribuzin metribuzin : A member of the class of 1,2,4-triazines that is 1,2,4-triazin-5(4H)-one substituted by an amino group at position 4, tert-butyl group at position 6 and a methylsulfanyl group at position 3.	2.15	1	1,2,4-triazines; cyclic ketone; organic sulfide	agrochemical; environmental contaminant; herbicide; xenobiotic
2,5-dimethyl-3-furancarboxanilide 2,5-dimethyl-3-furancarboxanilide: structure	2.15	1
moricizine hydrochloride moricizine hydrochloride : A hydrochloride salt obtained from equimola amounts of moricizine and hydrogen chloride.	2.15	1	hydrochloride	anti-arrhythmia drug
2-benzimidazolylguanidine 2-benzimidazolylguanidine: effects chloride efflux in tissue; RN given refers to parent cpd	2.15	1	aminoimidazole
diflubenzuron Diflubenzuron: An insect growth regulator which interferes with the formation of the insect cuticle. It is effective in the control of mosquitoes and flies.. diflubenzuron : A benzoylurea insecticide that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 4-chlorophenyl group, and a hydrogen attached to the other nitrogen is replaced bgy a 2,6-difluorobenzoyl group.	2.15	1	benzoylurea insecticide; monochlorobenzenes	insect sterilant
pentafluorobenzoyl-n-phenylethylamine [no description available]	2.15	1
thidiazuron [no description available]	2.15	1	ureas
phenthiazamine phenthiazamine: RN given refers to parent cpd	2.15	1
5,5-diphenylbarbituric acid 5,5-diphenylbarbituric acid: RN given refers to parent cpd	2.15	1
3-acetamidobenzoic acid N-acetyl-m-aminobenzoic acid: from Solanum laciniatum; structure in first source	2.15	1
dazoxiben hydrochloride [no description available]	2.15	1
succinylsulfanilamide [no description available]	2.15	1
benzylaminopurine benzylaminopurine: a plant growth regulator. N-benzyladenine : A member of the class of 6-aminopurines that is adenine in which one of the hydrogens of the amino group is replaced by a benzyl group.	2.15	1	6-aminopurines	cytokinin; plant metabolite
ciprofloxacin hydrochloride anhydrous [no description available]	2.15	1	hydrochloride	antibacterial drug; antiinfective agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
src-820 r [no description available]	2.15	1
n(4)-acetylsulfadiazine N(4)-acetylsulfadiazine: main metabolite of sulfadiazine. N(4)-acetylsulfadiazine : A sulfonamide that is benzenesulfonamide substituted by an acetylamino group at position 4 and a pyrimidin-2-yl group at the nitrogen atom. It is a metabolite of the drug sulfadiazine.	2.15	1	acetamides; pyrimidines; sulfonamide	marine xenobiotic metabolite
4-nitro-alpha-acetylamino-beta-hydroxypropiophenone 4-nitro-alpha-acetylamino-beta-hydroxypropiophenone: inhibitory agent for the differentiation of mammalian tuberculosis strains from other Mycobacteria	2.15	1
formetamide formetamide: RN given refers to cpd with unspecified isomeric designation	2.15	1
isbufylline isbufylline: RN from Toxlit	2.15	1
1,7-phenanthroline [no description available]	1.95	1	phenanthroline
phenylacetylglycine phenylacetylglycine : A N-acylglycine that is glycine substituted on nitrogen with a phenylacetyl group.	2.15	1	monocarboxylic acid amide; monocarboxylic acid; N-acylglycine	human metabolite; mouse metabolite
N-benzoylanthranilic acid N-benzoylanthranilic acid : An amidobenzoic acid comprising benzoic acid having a benzamido group at the 2-position.	2.15	1	amidobenzoic acid
butinoline [no description available]	2.15	1	diarylmethane
n-(2-carboxyphenyl)glycine [no description available]	2.15	1
n,n-dimethyl-4-anisidine [no description available]	2.15	1
n-benzoylpiperidine [no description available]	2.15	1	benzamides; N-acylpiperidine
2-phenylcyclopropanecarboxylic acid 2-phenylcyclopropanecarboxylic acid: RN given for (trans)-isomer; structure in first source	2.15	1
n-demethylantipyrine [no description available]	2.15	1	pyrazoles; ring assembly
3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine [no description available]	2.15	1	1,2,4-triazines
2-amino-5-bromopyridine [no description available]	2.15	1
n-benzoylalanine, (dl-ala)-isomer [no description available]	2.15	1	alanine derivative; N-acyl-amino acid	metabolite
bicinchoninic acid [no description available]	2.15	1
5-methyl-8-hydroxyquinoline 5-methyl-8-hydroxyquinoline: RN given refers to parent cpd; structure in first source & in Negwer, 5th ed, #1202	1.95	1	hydroxyquinoline
betamipron [no description available]	2.15	1	organonitrogen compound; organooxygen compound
benzoylpropionic acid benzoylpropionic acid: structure in first source. 4-oxo-4-phenylbutyric acid : A 4-oxo monocarboxylic acid that is butyric acid bearing oxo and phenyl substituents at position 4.	2.15	1	4-oxo monocarboxylic acid	hapten
Evoxine [no description available]	2.15	1	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle
1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid: precursor of mutagenic nitroso cpd in soy sauce; structure given in first source	2.15	1	harmala alkaloid
N-Benzylphthalimide [no description available]	2.15	1	isoindoles
pyromellitic diimide pyromellitic diimide: RN given refers to parent cpd	2.15	1
4'-bromosalicylanilide 4'-bromosalicylanilide: photoproduct from UV-irradiation of tribromsalan; structure	2.15	1
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane: methoxychlor metabolite	2.15	1	bisphenol
terephthalamide [no description available]	2.15	1	benzenedicarboxamide
3(2h)-pyridazinone, 4-chloro-5-(dimethylamino)-2-phenyl- [no description available]	2.15	1
2-nitrophenylacetic acid (2-nitrophenyl)acetic acid : A member of the class of phenylacetic acids that is phenylacetic acid in which the phenyl grup is substituted at the ortho- position by a nitro group.	2.15	1	C-nitro compound; phenylacetic acids
onychine [no description available]	2.15	1
4'-methoxyflavone 4'-methoxyflavone: from seeds of Psoralea corylifolia (Fabaceae); structure in first source	2.15	1	ether; flavonoids
1,3-diphenyl-2-aminopropane 1,3-diphenyl-2-aminopropane: structure given in the first source	2.15	1
2,2-diphenylpropionic acid 2,2-diphenylpropionic acid: RN given refers to parent cpd	2.15	1
3,4-dimethoxyphenylacetamide 3,4-dimethoxyphenylacetamide: structure	2.15	1
2-amino-5-bromobenzoic acid 2-amino-5-bromobenzoic acid: structure in first source	2.15	1
2-(1H-benzimidazol-2-yl)aniline 2-(1H-benzimidazol-2-yl)aniline : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a 2-aminophenyl group at position 2.	2.15	1	benzimidazoles; primary arylamine; substituted aniline	geroprotector
N-Acetylhomoveratrylamine [no description available]	2.15	1	acetamides
2-chlorobenzenesulfonamide [no description available]	2.15	1
4-nitrophenyl dimethylcarbamate [no description available]	2.15	1
8-(4-tolylsulfonylamino)quinoline 8-(4-tolylsulfonylamino)quinoline: has diabetogenic properties; can be used for fluorometric determination of zinc; structure given in first source	2.15	1	sulfonamide
5-methoxyindole-3-carbaldehyde [no description available]	2.15	1	indoles
ferroin ferroin: RN given refers to parent cpd	1.95	1
2-oxo-1,2-dihydroquinoline-4-carboxylic acid [no description available]	2.15	1	quinolinemonocarboxylic acid
6-methoxy-2,3,4,9-tetrahydropyrido[3,4-b]indol-1-one [no description available]	2.15	1	beta-carbolines
pd 147953 [no description available]	2.15	1
fenozan fenozan: do not confuse with the phenothiazine phenosan	2.15	1
5-phenylbarbituric acid 5-phenylbarbituric acid: RN given refers to parent cpd	2.15	1
diethylpropion hydrochloride diethylpropion hydrochloride : The hydrochloride salt of diethylpropion. A central stimulant and indirect-acting sympathomimetic, it is an appetite depressant and is used as an anoretic in the short term management of obesity.	2.15	1	hydrochloride	appetite depressant
1-(4'-nitrophenyl)-2-aminopropane-1,3-diol 1-(4'-nitrophenyl)-2-aminopropane-1,3-diol: chloramphenicol minus dichloroacetamide side chain; RN given refers to cpd without isomeric designation	2.15	1
beta-hydroxyphenylalanine beta-hydroxyphenylalanine: RN given refers to beta cpd	2.15	1
3-(n-salicyloyl)amino-1,2,4-triazole 3-(N-salicyloyl)amino-1,2,4-triazole: synthetic chelating agent used chiefly to inhibit corrosion of copper	2.15	1
7-chloro-4-aminoquinoline 7-chloro-4-aminoquinoline: structure given in first source	2.15	1	aminoquinoline
acridine-9-carboxylic acid [no description available]	2.15	1
1-phenazinecarboxylic acid 1-phenazinecarboxylic acid: from Streptomyces cinnamonensis; RN given refers to parent cpd; structure given in first source. phenazine-1-carboxylic acid : An aromatic carboxylic acid that is phenazine substituted at C-1 with a carboxy group.	2.15	1	aromatic carboxylic acid; monocarboxylic acid; phenazines	antifungal agent; antimicrobial agent; bacterial metabolite
4,5-diphenyl-1,5-dihydroimidazol-2-one [no description available]	2.15	1	stilbenoid
2-hydroxy-1,2-bis(methoxyphenyl)ethanone 2-hydroxy-1,2-bis(methoxyphenyl)ethanone: structure given in first source	2.15	1
4-methyl-N-(phenylmethyl)benzenesulfonamide [no description available]	2.15	1	sulfonamide
4-n-butylaminobenzoic acid 4-n-butylaminobenzoic acid: degradation product of tetracaine. 4-(butylamino)benzoic acid : 4-Aminobenzoic acid in which one of the hydrogens attached to the nitrogen is substituted by a butyl group.	2.15	1	aromatic amino acid
fluoren-9-ol [no description available]	2.15	1
1-(2-carboxyethyl)uracil [no description available]	2.15	1
1-benzylindole 1-benzylindole: structure	2.15	1
2,3-bis(2-pyridinyl)quinoxaline [no description available]	2.15	1	quinoxaline derivative
3,3',5,5'-tetrachlorobiphenyl-4,4'-diol 3,3',5,5'-tetrachlorobiphenyl-4,4'-diol : A member of the class of hydroxybiphenyls formed formally by chlorination of biphenyl-4,4'-diol at C-3, -3', -5 and -5'.	2.15	1	dichlorobenzene; hydroxybiphenyls
5-nitro-2-(1-piperidinyl)pyridine [no description available]	2.15	1	C-nitro compound
2-amino-5,7-dimethyl-1,8-naphthyridine 2-amino-5,7-dimethyl-1,8-naphthyridine: structure in first source	2.15	1
5-benzyloxytryptophan [no description available]	2.15	1
2,5-diethoxy-4-morpholinoaniline 2,5-diethoxy-4-morpholinoaniline: structure in first source	2.15	1
3-hydroxy-3-phenacyloxindole [no description available]	2.15	1
carbobenzoxyphenylalanine, (dl-phe)-isomer [no description available]	2.15	1
gamma-fagarine gamma-fagarine: active alkaloid of Chinese medicines from Dictamni radicis cortex (Rutaceae); structure given in first source	2.15	1	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle
3-carboxymethyl-6-benzyl-2,5-diketopiperazine 3-carboxymethyl-6-benzyl-2,5-diketopiperazine: formed in aqueous solution by aspartame; structure given in first source	2.15	1	organonitrogen compound; organooxygen compound
4-fluorobenzenesulfonamide 4-fluorobenzenesulfonamide: structure given in first source	2.15	1
emoxypine succinate emoxypine succinate: has antihypoxic effects	2.15	1
n-carbamyltryptophan N-carbamyltryptophan: RN given refers to (D)-isomer	2.15	1
2,4,6-trimethoxyacetophenone 2,4,6-trimethoxyacetophenone: structure in first source	2.15	1
1-(2-hydroxyethyl)-3,5-diphenyl-1h-pyrazole 1-(2-hydroxyethyl)-3,5-diphenyl-1H-pyrazole: structure given in first source	2.15	1
4-methyoxybenzoyl-n-glycine [no description available]	2.15	1	N-acylglycine
5-ethoxy-2-ethylmercaptobenzimidazole 5-ethoxy-2-ethylmercaptobenzimidazole: has activating effect on peritoneal macrophages; RN given does not give position for ethoxy group	2.15	1
5(6)-1(2h)-phthalazinonyl-4(1h)-benzimidazole-2-carbamate methyl ester [no description available]	2.15	1
n-phenyliminodiacetic acid [no description available]	2.15	1
teomorfolin teomorfolin: structure given in first source	2.15	1
1-(1,3-benzodioxol-5-yl)-3-(1-piperidinyl)-1-propanone [no description available]	2.15	1	benzodioxoles
n-(aminocarbonyl)-2-chlorobenzenesulfonamide [no description available]	2.15	1
3-hydroxy-2-quinoxalinepropionic acid [no description available]	2.15	1
8-(methylsulfonylamino)quinoline 8-(methylsulfonylamino)quinoline: has diabetogenic properties; structure given in first source	2.15	1
hydroxyl radical Hydroxyl Radical: The univalent radical OH. Hydroxyl radical is a potent oxidizing agent.	2.1	1	oxygen hydride; oxygen radical; reactive oxygen species
n(4)-acetylsulfamonomethoxine N(4)-acetylsulfamonomethoxine: main urinary metabolite of sulfamonomethoxine in pigs	2.15	1
8-(4-benzenesulfonylamino)quinoline 8-(4-benzenesulfonylamino)quinoline: has diabetogenic properties; structure given in first source	2.15	1
methindione methindione: used in treatment of epilepsy; RN given refers to parent cpd; structure	2.15	1
3,4-dihydroxybenzophenone 3,4-dihydroxybenzophenone: structure in first source	2.15	1
gamma-propanol [no description available]	2.15	1
2-[(3-oxo-1-cyclohexenyl)amino]benzonitrile [no description available]	2.15	1	benzenes; nitrile
isonicotinylamide gaba [no description available]	2.15	1
5-fluorotryptamine monohydrochloride [no description available]	2.15	1
4-iodo-n-(2-(4-morpholinyl)ethyl)benzamide 4-iodo-N-(2-(4-morpholinyl)ethyl)benzamide: the iodinated analog of moclobemide; structure given in first source	2.15	1
3-(hydroxyacetyl)indole 3-(hydroxyacetyl)indole: structure in first source	2.15	1	indoles
n-(4-aminophenylsulfonyl)morpholine compound 82 208: structure given in first source	2.15	1
1H-indol-3-yl-(4-methoxyphenyl)methanone [no description available]	2.15	1	N-acylindole
2-amino-5-phenyl-1,3,4-thiadiazole 2-amino-5-phenyl-1,3,4-thiadiazole: structure in first source	2.15	1
N-(1-phenylethyl)acetamide N-(1-phenylethyl)acetamide : A member of the class of acetamides resulting from the formal condensation of the amino group of 1-phenylethylamine with 1 mol eq. of acetic acid.	2.15	1	acetamides; secondary carboxamide
alpha-(trichloromethyl)-4-pyridineethanol alpha-(trichloromethyl)-4-pyridineethanol: activates caspase-3	2.15	1	pyridines
ml 204 ML 204: modulates both TRPC4 and TRPC5 channels; structure in first source	2.15	1
eudesmin eudesmin: RN refers to (1R-(1alpha,3aalpha,4alpha,6aalpha))-isomer; structure given in first source; very similar to pinoresinol	2.15	1
2-amino-4-methyl-3-nitropyridine [no description available]	2.15	1
4,4-bis(hydroxymethyl)-2-phenyl-2-oxazoline 4,4-bis(hydroxymethyl)-2-phenyl-2-oxazoline: Anticonvulsant	2.15	1
n-acetylhistidine [no description available]	2.15	1	histidine derivative; N-acetyl-amino acid
1-(1-oxo-2-phenylethyl)-4-piperidinecarboxylic acid [no description available]	2.15	1	acetamides
1-(4-chlorophenyl)-3-(2-ethoxyphenyl)urea [no description available]	2.15	1	ureas
4-methoxyxanthone 4-methoxyxanthone: a vasodilator; structure in first source	2.15	1
N-(4-nitrophenyl)-2-phenoxyacetamide [no description available]	2.15	1	C-nitro compound
1-phenylindolin-2-one 1-phenylindolin-2-one: structure in first source	2.15	1
1-(benzenesulfonyl)indole [no description available]	2.15	1	sulfonamide
2,4,4,6-Tetramethyl-1,4-dihydro-3,5-pyridinedicarbonitrile [no description available]	2.15	1	dihydropyridine
pifithrin mu 2-phenylacetylenesulfonamide: induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia cells; also inhibits Hsp70 and autophagy	2.15	1	benzenes
2-benzyloxybenzaldehyde [no description available]	2.15	1
2-guanidine-4-methylquinazoline 2-guanidine-4-methylquinazoline: structure given in first source	2.15	1
N-phenylcarbamic acid 2-phenoxyethyl ester [no description available]	2.15	1	carbamate ester
3,4-dihydro-2H-benzo[4,5]imidazo[2,1-b][1,3]thiazin-3-ol [no description available]	2.15	1	benzimidazoles
mequindox Mequindox: a synthetic quinoxaline 1,4-dioxide derivative which can effectively improve growth and feed efficiency in animals; structure in first source	2.15	1
5-amino-8-hydroxyquinoline 5-amino-8-hydroxyquinoline: structure in first source	1.95	1
N-[2-(dimethylamino)ethyl]-2,2-diphenylacetamide [no description available]	2.15	1	diarylmethane
Girgensonine [no description available]	2.15	1	nitrile
Dubinidine [no description available]	2.15	1	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle
N-[4-(methanesulfonamido)phenyl]acetamide [no description available]	2.15	1	sulfonamide
4-(2-oxazolo[4,5-b]pyridinyl)aniline [no description available]	2.15	1	1,3-oxazoles
2-[(4-nitrophenyl)methylthio]-1,3-benzoxazole [no description available]	2.15	1	benzoxazole
3-oxido-4,5-dihydro-[1,2,5]oxadiazolo[3,4-f]cinnolin-3-ium [no description available]	2.15	1	pyridazines
3-(2,4-difluoroanilino)-5,5-dimethyl-1-cyclohex-2-enone [no description available]	2.15	1	substituted aniline
1-phenyl-4-pyrazolol [no description available]	2.15	1	pyrazoles; ring assembly
3-(3,5-dimethyl-1-pyrazolyl)-1,2-benzothiazole 1,1-dioxide [no description available]	2.15	1	benzothiazoles
3-benzamido-2-benzofurancarboxamide [no description available]	2.15	1	benzofurans
N-[2-(4-methoxyphenyl)ethyl]acetamide [no description available]	2.15	1	acetamides
N-[2-(3-methylphenoxy)ethyl]-1H-1,2,4-triazole-5-carboxamide [no description available]	2.15	1	aromatic ether
2-(1H-indol-3-ylthio)acetic acid [no description available]	2.15	1	indoles
3-bromo-N-[2-(4-nitroanilino)ethyl]benzamide [no description available]	2.15	1	carbonyl compound; organohalogen compound
3-Methylbenzofuran-2-carboxylic acid [no description available]	2.15	1	benzofurans
5-(3,4-dimethoxyphenyl)-2H-tetrazole [no description available]	2.15	1	tetrazoles
1-(4-fluorophenyl)sulfonyl-4-(2-methoxyphenyl)piperazine [no description available]	2.15	1	piperazines
4-[[bis(2-hydroxyethyl)amino]methyl]-2,6-ditert-butylphenol [no description available]	2.15	1	alkylbenzene
2-phenylindole-3-carbaldehyde 2-phenylindole-3-carbaldehyde: structure in first source	2.15	1
4-(2-pyridinylthio)benzofuro[3,2-d]pyrimidine [no description available]	2.15	1	aryl sulfide
5-(4-nitrophenyl)-4-phenyl-2-thiazolamine [no description available]	2.15	1	C-nitro compound
3-[6-(4-aminophenyl)-2-phenyl-4-pyrimidinyl]aniline [no description available]	2.15	1	pyrimidines
7-methoxyisoflavone 7-methoxyisoflavone : A methoxyisoflavone that is isoflavone substituted by a methoxy group at position 7.	2.15	1	7-methoxyisoflavones
LSM-32392 [no description available]	2.15	1	monoterpenoid
N-[2-(1-cyclohexenyl)ethyl]-4-(4-morpholinylmethyl)benzamide [no description available]	2.15	1	benzamides
1-(1-benzimidazolyl)-3-(1-cyclohex-3-enylmethoxy)-2-propanol [no description available]	2.15	1	benzimidazoles
N-[2-(2-furanylmethylthio)ethyl]-4-methoxybenzenesulfonamide [no description available]	2.15	1	sulfonamide
3-acetamido-5-chloro-2-benzofurancarboxylic acid [no description available]	2.15	1	benzofurans
[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-(2,6-dimethoxyphenyl)methanone [no description available]	2.15	1	dimethoxybenzene
4-[4-methyl-6-(4-methyl-1-piperazinyl)-2-pyrimidinyl]morpholine [no description available]	2.15	1	N-arylpiperazine
haplamine haplamine: isolated from Haplophyllum acutifolium; structure in first source	2.15	1	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle
5-(3,4-dimethoxyphenyl)-1H-1,2,4-triazol-3-amine [no description available]	2.15	1	triazoles
2-ethoxy-N-[4-(4-morpholinylsulfonyl)phenyl]benzamide [no description available]	2.15	1	benzamides
2-[(5-methyl-1H-1,2,4-triazol-3-yl)thio]-1-phenylethanone [no description available]	2.15	1	aromatic ketone
1-ethyl-6-methoxy-4-oxo-3-quinolinecarboxylic acid [no description available]	2.15	1	quinolines
2-(pyridin-4-yl)-4-(pyrrolidin-1-yl)quinazoline 2-(pyridin-4-yl)-4-(pyrrolidin-1-yl)quinazoline : A member of the class of quinazolines that is quinazoline which is substituted at positions 2 and 4 by pyridin-4-yl and pyrrolidin-1-yl groups, respectively.	2.15	1	pyridines; pyrrolidines; quinazolines
scp 1 [no description available]	2.15	1
N-(3-acetamidophenyl)-4-methoxybenzamide [no description available]	2.15	1	benzamides
N-(3-acetamidophenyl)-3-chlorobenzamide [no description available]	2.15	1	benzamides
4-methoxy-N-(5-methyl-3-isoxazolyl)benzamide [no description available]	2.15	1	benzamides
N-(2-fluorophenyl)-4-phenylmethoxybenzamide [no description available]	2.15	1	benzamides
N-[4-(diethylamino)phenyl]-2-furancarboxamide [no description available]	2.15	1	aromatic amide; furans
N-(2-furanylmethyl)-2-benzofurancarboxamide [no description available]	2.15	1	benzofurans
5-(2-phenylethyl)-1,3,4-thiadiazol-2-amine [no description available]	2.15	1	aromatic amine; thiadiazoles
te 5 [no description available]	2.15	1
2-[[anilino(oxo)methyl]amino]-4,5-dimethyl-3-thiophenecarboxamide [no description available]	2.15	1	ureas
N-(4,6-dimethyl-2-pyrimidinyl)-1,3-benzothiazol-2-amine [no description available]	2.15	1	benzothiazoles
6-methylflavone 6-methylflavone: structure in first source	2.15	1
2-methoxy-N-(2-pyridinyl)benzamide [no description available]	2.15	1	benzamides
2-chloro-N-(2-phenylethyl)benzamide [no description available]	2.15	1	carbonyl compound; organohalogen compound
N1-(4H-1,2,4-triazol-4-yl)-4-nitrobenzamide [no description available]	2.15	1	C-nitro compound
N-[2-(1-cyclohexenyl)ethyl]-4-fluorobenzamide [no description available]	2.15	1	carbonyl compound; organohalogen compound
tioxazafen tioxazafen : A 1,2,4-oxadizole in which the hydrogens at positions 3 and 5 have been replaced by phenyl and thiophen-2-yl groups, respectively. It is used as a broad spectrum nematicidal seed treatment.	2.15	1	1,2,4-oxadiazole; thiophenes	agrochemical; nematicide
N-[5-(2-methylpropyl)-1,3,4-thiadiazol-2-yl]-2-thiophen-2-ylacetamide [no description available]	2.15	1	aromatic amide
1-(4-Methoxyphenyl)-2-nitroethylene 4-methoxy-beta-nitrostyrene: has vasodilator activity; structure in first source	2.15	1	methoxybenzenes
brd32048 BRD32048: inhibits ETV1 oncoprotein; structure in first source	2.15	1	methoxybenzenes; substituted aniline
2-(4-chloro-3-methylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide [no description available]	2.15	1	aromatic ether
2-(3,4-dichlorophenyl)imidazo[1,2-a]pyrimidine [no description available]	2.15	1	imidazoles
5-(2-phenyl-4-triazolyl)-2H-tetrazole [no description available]	2.15	1	triazoles
N-cyclohexyl-2,3-dihydroindole-1-carboxamide [no description available]	2.15	1	indolyl carboxylic acid
4-(benzylsulfanyl)thieno[2,3-d]pyrimidine 4-(benzylsulfanyl)thieno[2,3-d]pyrimidine : A thienopyrimidine that is thieno[2,3-d]pyrimidine which is substituted at position 4 by a benzylsulfanediyl group.	2.15	1	aryl sulfide; benzenes; thienopyrimidine
2-methyl-5-(5-methyl-2-furanyl)-3-(1-pyrrolyl)-4-thieno[2,3-d]pyrimidinone [no description available]	2.15	1	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
1-[2-(dimethylamino)ethyl]-5-methoxy-N-methyl-2-indolecarboxamide [no description available]	2.15	1	indolecarboxamide
N-(5-ethyl-1,3,4-thiadiazol-2-yl)-3-methoxybenzamide [no description available]	2.15	1	benzamides
4-(1H-benzimidazol-2-yl)quinoline [no description available]	2.15	1	quinolines
1-(4-Chlorophenyl)-2-[(1-methyl-1H-imidazol-2-yl)thio]ethan-1-one [no description available]	2.15	1	aromatic ketone
N-(2,5-dimethylphenyl)-2-benzofurancarboxamide [no description available]	2.15	1	aromatic amide; furans
N-(4-methoxyphenyl)-2-benzofurancarboxamide [no description available]	2.15	1	aromatic amide; furans
2-(9h-xanthen-9-yl)-malonic acid [no description available]	2.15	1	xanthenes
1-(1,3-benzothiazol-2-yl)-3-phenylurea [no description available]	2.15	1	ureas
1-hydroxy-2-phenyl-1,5,6,7-tetrahydro-4H-benzimidazol-4-one [no description available]	2.15	1	imidazoles
N-(4-acetamidophenyl)-2-bromobenzamide [no description available]	2.15	1	benzamides
4-bromo-N-phenacylbenzamide [no description available]	2.15	1	aromatic ketone
1-(2,3-dihydroindol-1-yl)-2-(phenylthio)ethanone [no description available]	2.15	1	indoles
N-[6-methyl-2-(4-methylphenyl)-5-benzotriazolyl]-3-pyridinecarboxamide [no description available]	2.15	1	triazoles
N,N-dimethyl-N'-p-tolylsulfamide N,N-dimethyl-N'-p-tolylsulfamide : A member of the class of sulfamides that is N,N-dimethylsulfuric diamide substituted by a 4-methylphenyl group at the amino nitrogen atom. It is a metabolite of the agrochemical tolylfluanid.	2.15	1	sulfamides	marine xenobiotic metabolite
2-(1-piperidinylmethyl)phenol 2-(1-piperidinylmethyl)phenol: structure in first source	2.15	1
2,6-bis(benzimidazol-2-yl)pyridine 2,6-bis(benzimidazol-2-yl)pyridine: structure in first source	2.15	1	benzimidazoles
1-cyclohexyl-3-(2-phenylethyl)urea [no description available]	2.15	1	benzenes
1-(3,5-dichlorophenyl)-3-phenylurea [no description available]	2.15	1	ureas
1-(cyclohexylmethyl)-4-phenylpiperazine [no description available]	2.15	1	piperazines
N-phenethyl-2-furamide [no description available]	2.15	1	aromatic amide; heteroarene
paromomycin sulfate [no description available]	2.15	1
N,N,2-trimethyl-1-phenyl-5-benzimidazolesulfonamide [no description available]	2.15	1	benzimidazoles
N-(phenylmethyl)-4-(3-pyridinyl)-2-thiazolamine [no description available]	2.15	1	aralkylamine
N-(4-hydroxy-2-methyl-5-propan-2-ylphenyl)benzenesulfonamide [no description available]	2.15	1	monoterpenoid
2-amino-5-ethyl-4-(2-furanyl)-6-propyl-3-pyridinecarbonitrile [no description available]	2.15	1	nitrile; pyridines
2-ethoxy-N-[5-(methoxymethyl)-1,3,4-thiadiazol-2-yl]benzamide [no description available]	2.15	1	benzamides
vu0099704 VU0099704: an antagonist of protease activated receptor 4 (PAR-4); structure in first source	2.15	1
3-(4-chlorophenyl)-2,5-dimethyl-1H-pyrazolo[1,5-a]pyrimidin-7-one [no description available]	2.15	1	pyrazoles; ring assembly
1-(2-chloro-6-fluorophenyl)-[1,2,4]triazolo[4,3-a]quinoline [no description available]	2.15	1	triazoles
2-methyl-N-(1-methyl-2,3-dihydropyrrolo[2,3-b]quinolin-4-yl)propanamide [no description available]	2.15	1	pyrroloquinoline
2-methyl-5-[(2-methyl-4-quinolinyl)thio]-1,3,4-thiadiazole [no description available]	2.15	1	aryl sulfide
5-methyl-1-(4-nitrophenyl)-2-oxo-2,5-dihydro-1h-pyrido(3,2-b)indole-3-carbonitrile VRX-413638: structure in first source	2.15	1
(3-hydroxy-5,6,7,8-tetrahydro-4H-cyclohepta[d]imidazol-2-yl)-phenylmethanone [no description available]	2.15	1	aromatic ketone
2-fluoro-N-phenacylbenzamide [no description available]	2.15	1	aromatic ketone
4-(methoxymethyl)-6-methyl-2-(2-methylanilino)-3-pyridinecarbonitrile [no description available]	2.15	1	nitrile; pyridines
1-azepanyl-[2-methoxy-4-(methylthio)phenyl]methanone [no description available]	2.15	1	carbonyl compound; thiol
GS4012 free base GS4012 free base : A member of the class of pyridines that is 2-(pyridin-4-yl)ethane-1-thiol in which the thiol hydrogen is replaced by a 4-methoxyphenyl group.	2.15	1	aryl sulfide; monomethoxybenzene; pyridines	VEGF activator
N-[1-(4-methylphenyl)-5-benzimidazolyl]acetamide [no description available]	2.15	1	benzimidazoles
2-(4-methylanilino)-1-(4-nitrophenyl)ethanone [no description available]	2.15	1	aromatic ketone
N-(2,6-dimethylphenyl)-N(2)-(3,5-dimethylphenyl)glycinamide N-(2,6-dimethylphenyl)-N(2)-(3,5-dimethylphenyl)glycinamide : An amino acid amide obtained by the formal condensation of 2,6-dimethylaniline with N-(3,5-dimethylphenyl)glycine.	2.15	1	amino acid amide; glycine derivative
2-[4-[(3-fluorophenyl)methyl]-1-piperazinyl]pyrimidine [no description available]	2.15	1	N-arylpiperazine
1-[(3,4-dimethoxyphenyl)methyl]-4-(2,3-dimethylphenyl)piperazine [no description available]	2.15	1	piperazines
4-Piperidinobenzoic acid [no description available]	2.15	1	piperidines
1-(2-methoxyphenyl)-4-(3-thiophenylmethyl)piperazine [no description available]	2.15	1	piperazines
N-(1-methyl-2,3-dihydropyrrolo[2,3-b]quinolin-4-yl)-2-(1-pyrrolidinyl)acetamide [no description available]	2.15	1	pyrroloquinoline
4-[(1H-benzimidazol-2-ylthio)methyl]-2-thiazolamine [no description available]	2.15	1	benzimidazoles
4-[(4-phenyl-2-thiazolyl)amino]benzenesulfonamide [no description available]	2.15	1	sulfonamide
N-[7-(1-oxopropyl)-2,3-dihydro-1,4-benzodioxin-6-yl]benzamide [no description available]	2.15	1	benzodioxine
N-[3-chloro-4-(1-pyrrolidinyl)phenyl]-2-furancarboxamide [no description available]	2.15	1	aromatic amide; furans
n-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine N-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine: an SK channel inhibitor	2.15	1
8-(3,5-dimethyl-1-pyrazolyl)quinoline [no description available]	2.15	1	quinolines
2'-nitroflavone 2'-nitroflavone: has antineoplastic activity	2.15	1
N-(4-methoxyphenyl)-3,4-dihydroquinolin-2-amine [no description available]	2.15	1	aminoquinoline
1-(3-nitrophenyl)-3-phenyl-2-propyn-1-one [no description available]	2.15	1	aromatic compound
vrt 532 VRT 532: a CFTR potentiator; structure in first source	2.15	1
4-[[4-(2,5-dimethylphenyl)-1-piperazinyl]methyl]-2-methoxyphenol [no description available]	2.15	1	piperazines
1-piperonylpiperidine 1-piperonylpiperidine: an AMPA receptor modulator; structure in first source	2.15	1
2-[(3-fluorophenyl)methyl-(phenylmethyl)amino]ethanol [no description available]	2.15	1	aromatic amine
2-methoxy-4-[[2-(methylthio)anilino]methyl]phenol [no description available]	2.15	1	aromatic amine
6-ethyl-5-methyl-2-thiophen-2-yl-1H-pyrazolo[1,5-a]pyrimidin-7-one [no description available]	2.15	1	pyrazolopyrimidine
N-[4-(2-methyl-4-thiazolyl)phenyl]benzamide [no description available]	2.15	1	benzamides
N-(6-phenyl-5-imidazo[2,1-b]thiazolyl)benzamide [no description available]	2.15	1	imidazoles
2-(phenylmethylthio)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole [no description available]	2.15	1	aryl sulfide
5-methyl-N-(4,5,6-trimethyl-2-pyrimidinyl)-1,3-benzoxazol-2-amine [no description available]	2.15	1	benzoxazole
1-(4-methoxyphenyl)-3-(6-methyl-2-pyridinyl)urea [no description available]	2.15	1	ureas
2-{[hydroxy(2-methoxyphenyl)methylidene]amino}acetic acid [no description available]	2.15	1	N-acylglycine
(4-methoxyphenyl)-(3-methyl-2-propyl-4-imidazolyl)methanone [no description available]	2.15	1	aromatic ketone
N-(3-acetamidophenyl)-2-chlorobenzamide [no description available]	2.15	1	benzamides
N4,N4-dimethyl-N1-(4-nitro-1,1-dioxo-2,5-dihydrothiophen-3-yl)benzene-1,4-diamine [no description available]	2.15	1	dialkylarylamine; tertiary amino compound
2-bromo-N-(3-methoxyphenyl)benzamide [no description available]	2.15	1	benzamides
2-methoxy-4-[(4-methyl-1,4-diazepan-1-yl)methyl]-6-nitrophenol [no description available]	2.15	1	aromatic ether; C-nitro compound
3-[[(2,5-dimethyl-3-furanyl)-oxomethyl]amino]benzoic acid [no description available]	2.15	1	aromatic amide; furans
1-(4-ethoxyphenyl)-3-(6-quinoxalinyl)urea [no description available]	2.15	1	quinoxaline derivative
2-(dimethylsulfamoylamino)-9H-fluorene [no description available]	2.15	1	fluorenes
4-chloro-1-ethyl-3-nitro-2-quinolinone [no description available]	2.15	1	nitro compound; quinolines
4-chloro-3-nitro-1-(phenylmethyl)-2-quinolinone [no description available]	2.15	1	quinolines
2,5-dimethyl-1-(phenylmethyl)pyrrole-3,4-dicarboxaldehyde [no description available]	2.15	1	arenecarbaldehyde
2-(2-chloro-6-fluorophenyl)-1-(2,4-dihydroxyphenyl)ethanone [no description available]	2.15	1	stilbenoid
4-methyl-N-(3-nitrophenyl)-5-phenyl-3-thiophenecarboxamide [no description available]	2.15	1	aromatic amide
N-(5-amino-1-phenyl-1,2,4-triazol-3-yl)-2,2,2-trichloroacetamide [no description available]	2.15	1	triazoles
N-(2-fluoro-5-methylphenyl)-3-phenylpropanamide [no description available]	2.15	1	anilide
N-[(4-fluorophenyl)methyl]-2-thiophen-2-ylacetamide [no description available]	2.15	1	organofluorine compound
4-tert-butyl-N-(1,4-dioxo-2,3-dihydrophthalazin-5-yl)benzamide [no description available]	2.15	1	phthalazines
N-[2-(2-methylpropyl)-1,3-dioxo-5-isoindolyl]-2-furancarboxamide [no description available]	2.15	1	phthalimides
6-(1,4,5,7-tetramethyl-6-pyrrolo[3,4-d]pyridazinyl)quinoline [no description available]	2.15	1	quinolines
2-(3,4-dimethoxyphenyl)-1-(2,4,6-trihydroxyphenyl)ethanone [no description available]	2.15	1	stilbenoid
5-(3-chloro-4-methylphenyl)-3-pyridin-4-yl-1,2,4-oxadiazole [no description available]	2.15	1	oxadiazole; ring assembly
5-(phenylmethyl)-3-(2-pyridinyl)-1,2,4-oxadiazole [no description available]	2.15	1	pyridines
2-methyl-5-(1-pyrrolidinyl)isoindole-1,3-dione [no description available]	2.15	1	phthalimides
(2'-(4-aminophenyl)-(2,5'-bi-1h-benzimidazol)-5-amine) [no description available]	2.15	1	benzimidazoles
N-(4-bromo-2-fluorophenyl)-2-methyl-3-furancarboxamide [no description available]	2.15	1	aromatic amide; furans
6,7,8,9-tetrahydro-5H-carbazole-3-carbohydrazide [no description available]	2.15	1	carbazoles
N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-pyrazinecarboxamide [no description available]	2.15	1	primary carboxamide; pyrazines; secondary carboxamide
N-(1,3-benzodioxol-5-yl)-5-methyl-2-furancarboxamide [no description available]	2.15	1	benzodioxoles
1-cyclohexyl-3-(2,3-dihydro-1,4-benzodioxin-6-yl)urea [no description available]	2.15	1	benzodioxine
8-[(2-methyl-5-nitro-1,2,4-triazol-3-yl)thio]quinoline [no description available]	2.15	1	aryl sulfide
1-[2-(2-chlorophenoxy)ethyl]benzimidazole [no description available]	2.15	1	benzimidazoles
4,5-dimethyl-2-[4-(3-nitrophenyl)-2-thiazolyl]-1H-pyrazol-3-one [no description available]	2.15	1	C-nitro compound
2-(4-fluoro-N-methylsulfonylanilino)-N-(3-methylphenyl)acetamide [no description available]	2.15	1	sulfonamide
1-(4-fluorophenyl)-2-(2-pyridinylthio)ethanone [no description available]	2.15	1	aromatic ketone
3-methyl-6-(1-pyrrolidinyl)-[1,2,4]triazolo[4,3-b]pyridazine [no description available]	2.15	1	triazolopyridazine
N-(3-acetylphenyl)-2-thiophen-2-ylacetamide [no description available]	2.15	1	aromatic ketone
oncrasin-1 oncrasin-1: an antineoplastic agent; structure in first source. oncrasin-1 : A member of the class of indoles that is 1H-indole substituted by 4-chlorobenzyl and formyl groups at positions 1 and 3, respectively. It is an anti-cancer agent that is active against lung cancer cells with K-Ras mutations.	2.15	1	arenecarbaldehyde; indoles; monochlorobenzenes	antineoplastic agent; apoptosis inducer
N-[2-(4-fluorophenyl)ethyl]-4-nitrobenzamide [no description available]	2.15	1	C-nitro compound
5-(1-methyl-2-benzimidazolyl)-2-thiophenecarboxaldehyde [no description available]	2.15	1	benzimidazoles
N-(4-anilinophenyl)-2-methylpropanamide [no description available]	2.15	1	anilide
N-(2-fluorophenyl)-3-phenylpropanamide [no description available]	2.15	1	anilide
1-[(Phenylthio)acetyl]piperidine [no description available]	2.15	1	N-acylpiperidine
N-(3-hydroxyphenyl)-5-methyl-3-furancarboxamide [no description available]	2.15	1	aromatic amide; furans
3-(4-methoxyphenyl)-5-(4-methylphenyl)-1,2,4-oxadiazole [no description available]	2.15	1	oxadiazole; ring assembly
4-[(4-carboxy-2,6-dimethoxyphenoxy)methyl]-5-methyl-2-furancarboxylic acid [no description available]	2.15	1	trihydroxybenzoic acid
4-(4-morpholinylmethyl)-3-quinolinol [no description available]	2.15	1	quinolines
2-bromo-N-[3-(1-oxopropylamino)phenyl]benzamide [no description available]	2.15	1	benzamides
3-acetyl-2-methylbenzo[f]benzofuran-4,9-dione [no description available]	2.15	1	naphthofuran
5-(4-chlorophenyl)-N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-furancarboxamide [no description available]	2.15	1	aromatic amide; heteroarene
1-azepanyl-[4-[(phenylthio)methyl]phenyl]methanone [no description available]	2.15	1	benzamides
1-(5-ethyl-2,4-dihydroxyphenyl)-2-(2-fluorophenoxy)ethanone [no description available]	2.15	1	aromatic ketone
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(2-nitrophenyl)acetamide [no description available]	2.15	1	acetamides
3,4,5-triethoxy-N-(1H-1,2,4-triazol-5-yl)benzamide [no description available]	2.15	1	benzamides
1-propylsulfonyl-4-(2-pyridinyl)piperazine [no description available]	2.15	1	piperazines; pyridines
2-(2-phenylethylthio)-3-pyridinecarboxylic acid [no description available]	2.15	1	aromatic carboxylic acid; pyridines
2-(2,3-dimethylphenoxy)-N-pyridin-4-ylacetamide [no description available]	2.15	1	aromatic ether
2-[[anilino(oxo)methyl]amino]-N-(phenylmethyl)benzamide [no description available]	2.15	1	benzamides
N-(5-acetyl-4-methyl-2-thiazolyl)-5-bromo-2-furancarboxamide [no description available]	2.15	1	thiazoles
1-cyclohexyl-3-(3-ethylphenyl)urea [no description available]	2.15	1	ureas
n-phenylpiracetam N-phenylpiracetam: structure given in first source	2.15	1
2-[(1-methyl-5-tetrazolyl)thio]-N-(2-phenylphenyl)acetamide [no description available]	2.15	1	biphenyls
N-[3-chloro-4-(1-pyrrolidinyl)phenyl]-2-nitrobenzamide [no description available]	2.15	1	benzamides
4-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-N-(2,6-dimethylphenyl)benzamide [no description available]	2.15	1	isoquinolines
5-(4-bromophenyl)-N-(2-methoxyphenyl)-2-furancarboxamide [no description available]	2.15	1	aromatic amide; furans
3-[[(3,5-dichloro-4-ethoxyphenyl)-oxomethyl]amino]benzoic acid [no description available]	2.15	1	benzamides
1,4-bis(thiophen-2-ylsulfonyl)piperazine [no description available]	2.15	1	N-sulfonylpiperazine; thiophenes
2-bromo-N-[3-(1-oxobutylamino)phenyl]benzamide [no description available]	2.15	1	benzamides
1-(2-fluorophenyl)-4-[(6-nitro-1,3-benzodioxol-5-yl)methyl]piperazine [no description available]	2.15	1	piperazines
n-(1-benzyl-4-piperidinyl)-2,4-dichlorobenzamide N-(1-benzyl-4-piperidinyl)-2,4-dichlorobenzamide: inhibits the betaine-GABA transporter 1; structure in first source	2.15	1
2-[[2-(5-methyl-2-thiophenyl)-2-oxoethyl]thio]-3-phenyl-4-quinazolinone [no description available]	2.15	1	quinazolines
1-(2,1,3-benzothiadiazol-5-yl)-3-[4-(4-morpholinyl)phenyl]urea [no description available]	2.15	1	morpholines
ethyl 4-{N-[(4-chlorophenyl)sulfonyl]-N-methylglycyl}piperazine-1-carboxylate ethyl 4-{N-[(4-chlorophenyl)sulfonyl]-N-methylglycyl}piperazine-1-carboxylate : A sulfonamide in which the nitrogen carries methyl and 2-[4-(ethoxycarbonyl)piperazin-1-yl]-2-oxoethyl substituents and the sulfonyl a 4-chlorophenyl group.	2.15	1	carbamate ester; sulfonamide
LSM-4563 [no description available]	2.15	1	aromatic ketone
1-(4-chloro-3-methoxyphenyl)sulfonyl-4-phenylpiperazine [no description available]	2.15	1	piperazines
N-[4-[(3,4-dimethoxyphenyl)sulfamoyl]phenyl]acetamide [no description available]	2.15	1	sulfonamide
4-chloro-3-(1-piperidinylsulfonyl)-N-(2-thiazolyl)benzamide [no description available]	2.15	1	sulfonamide
1-(2,5-dimethoxyphenyl)sulfonyl-4-(phenylmethyl)piperazine [no description available]	2.15	1	sulfonamide
2-(4-methoxyphenyl)-N-[4-[(5-methyl-3-isoxazolyl)sulfamoyl]phenyl]acetamide [no description available]	2.15	1	sulfonamide
4-[4-(benzenesulfonyl)-1-piperazinyl]-2-methylquinoline [no description available]	2.15	1	piperazines; pyridines
1-(6-methoxy-2,2,4-trimethyl-1-quinolinyl)-2-[[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]thio]ethanone [no description available]	2.15	1	quinolines
N2-phenyl-6-[[(1-phenyl-5-tetrazolyl)thio]methyl]-1,3,5-triazine-2,4-diamine [no description available]	2.15	1	tetrazoles
2-[(4,6-dimethyl-2-pyrimidinyl)thio]-N-(4,5-diphenyl-2-oxazolyl)acetamide [no description available]	2.15	1	1,3-oxazoles
2-(4-bromophenyl)-1-[4-(2-pyridinyl)-1-piperazinyl]ethanone [no description available]	2.15	1	piperazines; pyridines
2-amino[1,3]thiazolo[4,5-d]pyrimidine-5,7-diol [no description available]	2.15	1	thiazolopyrimidine
3-[[(2-cyclohexyl-1,3-dioxo-5-isoindolyl)-oxomethyl]amino]benzoic acid [no description available]	2.15	1	aromatic amide
3-[[[3-(1-azepanylsulfonyl)-4-chlorophenyl]-oxomethyl]amino]benzoic acid [no description available]	2.15	1	benzamides
2-(4-bromophenyl)-N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)acetamide [no description available]	2.15	1	acetamides
5-(1,3-benzodioxol-5-ylsulfamoyl)-2-methoxybenzoic acid [no description available]	2.15	1	methoxybenzoic acid
N-cycloheptyl-1-(4-methylphenyl)sulfonyl-4-piperidinecarboxamide [no description available]	2.15	1	sulfonamide
3-(2-chlorophenyl)-5-methyl-N-[4-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]-4-isoxazolecarboxamide [no description available]	2.15	1	aromatic amide
N-[3-[[(4-nitrophenyl)-oxomethyl]amino]phenyl]-2-furancarboxamide [no description available]	2.15	1	benzamides
3-methyl-1,5-dithiophen-2-ylpentane-1,5-dione [no description available]	2.15	1	aromatic ketone
N-(2-methyl-1,3-benzothiazol-6-yl)-4-(4-morpholinylsulfonyl)benzamide [no description available]	2.15	1	sulfonamide
4-(dimethylsulfamoyl)-N-(4-thiophen-2-yl-2-thiazolyl)benzamide [no description available]	2.15	1	sulfonamide
3-chloro-N-[4-[(1-oxo-2-phenylethyl)amino]phenyl]benzamide [no description available]	2.15	1	benzamides
N-(3,4-dimethoxyphenyl)-4-[(4-phenyl-1-piperazinyl)methyl]benzamide [no description available]	2.15	1	benzamides
stk295900 [no description available]	2.15	1
1-(3-chlorophenyl)-4-[(3,4,5-trimethoxyphenyl)methyl]piperazine [no description available]	2.15	1	piperazines
2-[4-[[4-(4-methoxyphenyl)-1-phthalazinyl]amino]phenyl]acetamide [no description available]	2.15	1	pyridazines; ring assembly
1-(2-fluorophenyl)-3-[5-(2-fluorophenyl)-1,3,4-thiadiazol-2-yl]urea [no description available]	2.15	1	ureas
N-[5-[(4-methoxyphenyl)methyl]-1,3,4-thiadiazol-2-yl]-2-furancarboxamide [no description available]	2.15	1	methoxybenzenes
N-(1,3-benzodioxol-5-yl)-4-methyl-1-phthalazinamine [no description available]	2.15	1	phthalazines
SMER 28 SMER 28 : A member of the class of quinazolines that is quinazoline which is substituted by a prop-2-en-1-ylnitrilo group and a bromo group at positions 4 and 6, respectively. It is a modulator of mammalian autophagy.	2.15	1	organobromine compound; quinazolines; secondary amino compound	autophagy inducer
N-[4-(4-morpholinyl)phenyl]carbamic acid butyl ester [no description available]	2.15	1	morpholines
4-(4-chlorophenoxy)-1-(4-morpholinyl)-1-butanone [no description available]	2.15	1	aromatic ether
4-(4-chlorophenoxy)-1-(1-piperidinyl)-1-butanone [no description available]	2.15	1	N-acylpiperidine
N-(3-phenylpropyl)methanesulfonamide [no description available]	2.15	1	benzenes
4-acetamido-N-(2-methoxyethyl)benzamide [no description available]	2.15	1	amidobenzoic acid
2-methyl-N-(2,3,4,5,6-pentafluorophenyl)-3-furancarboxamide [no description available]	2.15	1	aromatic amide; furans
3,4-dihydro-2H-quinolin-1-yl-(4-propoxyphenyl)methanone [no description available]	2.15	1	quinolines
5-bromo-N-(2-phenylphenyl)-2-furancarboxamide [no description available]	2.15	1	aromatic amide; furans
2-[2-(4-chlorophenoxy)ethylthio]pyrimidine [no description available]	2.15	1	aromatic ether
3-(3-bromoanilino)-1-(5-methyl-2-furanyl)-1-propanone [no description available]	2.15	1	aralkylamine
4-[2-(4-bromo-2-chlorophenoxy)-1-oxoethyl]-1-piperazinecarboxylic acid ethyl ester [no description available]	2.15	1	piperazinecarboxylic acid
2-[2-[[3-(1,3-benzoxazol-2-yl)anilino]-oxomethyl]phenyl]benzoic acid [no description available]	2.15	1	benzamides
1-[2-(2-chlorophenoxy)ethoxy]-2-methoxy-4-methylbenzene [no description available]	2.15	1	methoxybenzenes
N-[4-[(4-sulfamoylphenyl)sulfamoyl]phenyl]cyclopropanecarboxamide [no description available]	2.15	1	sulfonamide
4-[2-[2-(4-bromo-2-chlorophenoxy)ethoxy]ethyl]morpholine [no description available]	2.15	1	aromatic ether
N-[2-(2-phenylphenoxy)ethyl]-2-furancarboxamide [no description available]	2.15	1	biphenyls
5,6,7,8-tetrafluoro-2-(2,3,4,5,6-pentafluorophenyl)-4h-1-benzopyran-4-one 5,6,7,8-tetrafluoro-2-(2,3,4,5,6-pentafluorophenyl)-4H-1-benzopyran-4-one: structure in first source	2.15	1
2-[bis(5-methyl-2-furanyl)methyl]-6-nitrophenol [no description available]	2.15	1	nitrophenol
2-(4-nitrophenyl)-N-(2-oxolanylmethyl)-4-quinazolinamine [no description available]	2.15	1	quinazolines
2-(4-hydroxy-1,3-thiazol-2-yl)-1-phenylethan-1-one [no description available]	2.15	1	aromatic ketone
Methyl(2-furoylamino)acetic acid [no description available]	2.15	1	N-acyl-amino acid
5-nitro-8-(1-pyrrolidinyl)quinoline [no description available]	2.15	1	nitro compound; quinolines
2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)-N-phenylacetamide [no description available]	2.15	1	amino acid amide
2-[(4-methylphenyl)sulfonylamino]pentanoic acid [no description available]	2.15	1	sulfonamide
4,6-dimorpholino-n-(4-nitrophenyl)-1,3,5-triazin-2-amine 4,6-dimorpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine: an mTOR activator; structure in first source	2.15	1
1-[(3-chlorophenyl)methyl]-N,N-diethyl-3-piperidinecarboxamide [no description available]	2.15	1	piperidines
1-(2,6-dimethyl-1-piperidinyl)-2-phenylethanone [no description available]	2.15	1	acetamides
2-amino-7-methyl-5-oxo-4-(2,3,4-trimethoxyphenyl)-4,6,7,8-tetrahydro-1-benzopyran-3-carbonitrile [no description available]	2.15	1	methoxybenzenes
3-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-1-phenylpyrrolidine-2,5-dione [no description available]	2.15	1	pyrrolidines
1-(4-bromophenyl)-3-(diethylamino)pyrrolidine-2,5-dione [no description available]	2.15	1	pyrrolidines
4-(5,6-diphenyl-1,2,4-triazin-3-yl)morpholine [no description available]	2.15	1	dialkylarylamine; tertiary amino compound
(3,5-Dimethyl-1-adamantyl)amine nitrate [no description available]	2.15	1	nitrates
1-(4-tert-butylphenoxy)-3-(1H-1,2,4-triazol-5-ylthio)-2-propanol [no description available]	2.15	1	alkylbenzene
N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-2-adamantanamine [no description available]	2.15	1	N-alkylpyrrolidine
4-phenyl-N-(pyridin-4-ylmethyl)-2-butanamine [no description available]	2.15	1	aralkylamine
N-(5-nitro-2-pyridinyl)cyclopropanecarboxamide [no description available]	2.15	1	aromatic amide
3-[(4-bromophenyl)methyl]-4-(4-methoxyanilino)-4-oxobutanoic acid [no description available]	2.15	1	anilide
3-ethyl-N-(2H-tetrazol-5-yl)-1-adamantanecarboxamide [no description available]	2.15	1	aromatic amide
N-(4-propan-2-ylphenyl)-3-bicyclo[2.2.1]heptanecarboxamide [no description available]	2.15	1	monoterpenoid
4-chloro-N-[2-(4-nitroanilino)ethyl]benzamide [no description available]	2.15	1	carbonyl compound; organohalogen compound
2-[(2,3-dihydro-1,4-benzodioxin-6-ylamino)-oxomethyl]-1-cyclohexanecarboxylic acid [no description available]	2.15	1	benzodioxine
2,4-dichloro-6-[1-(4-morpholinyl)-3-phenylprop-2-ynyl]phenol [no description available]	2.15	1	aromatic compound
2-[[1-(4-ethoxyphenyl)-2,5-dioxo-3-pyrrolidinyl]amino]acetonitrile [no description available]	2.15	1	pyrrolidines
1-ethoxy-3-(2-methoxy-4-prop-2-enylphenoxy)-2-propanol [no description available]	2.15	1	methoxybenzenes
6-amino-4-(3-chlorophenyl)-3-methyl-1-(phenylmethyl)-4H-pyrano[2,3-c]pyrazole-5-carbonitrile [no description available]	2.15	1	organochlorine compound; pyranopyrazole
1-(2-chlorophenoxy)-3-(2-methyl-1-benzimidazolyl)-2-propanol [no description available]	2.15	1	benzimidazoles
N-[2-furanyl-(8-hydroxy-7-quinolinyl)methyl]-2-methylpropanamide [no description available]	2.15	1	hydroxyquinoline
N-(2-hydroxy-5-methylphenyl)-2-furancarboxamide [no description available]	2.15	1	aromatic amide; furans
4-amino-7,8,9,10-tetrahydro-6H-pyrimido[3,4]pyrrolo[3,5-a]azepine-11-carbonitrile [no description available]	2.15	1	organic heterobicyclic compound; organonitrogen heterocyclic compound
1-(3,5-dimethylphenyl)-3-(1H-1,2,4-triazol-5-ylthio)pyrrolidine-2,5-dione [no description available]	2.15	1	pyrrolidines
6-[(3,4-difluoroanilino)-oxomethyl]-1-cyclohex-3-enecarboxylic acid [no description available]	2.15	1	anilide
4-[(3-cyano-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-yl)amino]-4-oxobutanoic acid [no description available]	2.15	1	organosulfur heterocyclic compound
[3-methyl-4-[oxo(thiophen-2-yl)methyl]-1-piperazinyl]-thiophen-2-ylmethanone [no description available]	2.15	1	aromatic amide; thiophenes
[4-(2-methoxyphenyl)-1-piperazinyl]-[4-[(phenylthio)methyl]phenyl]methanone [no description available]	2.15	1	piperazines
N-(3,3,5-trimethylcyclohexyl)-1H-1,2,4-triazole-5-carboxamide [no description available]	2.15	1	aromatic amide; heteroarene
4-[2-nitro-5-[4-(phenylmethyl)sulfonyl-1-piperazinyl]phenyl]morpholine [no description available]	2.15	1	piperazines
5-(4-ethylsulfonyl-1-piperazinyl)-2-nitro-N-(3-pyridinylmethyl)aniline [no description available]	2.15	1	piperazines
2-[[5-[(1,3-benzothiazol-2-ylthio)methyl]-4-methyl-1,2,4-triazol-3-yl]thio]-N-[2-(4-morpholinyl)ethyl]acetamide [no description available]	2.15	1	benzothiazoles
N-ethyl-N-[2-[(5-nitro-8-quinolinyl)amino]ethyl]benzenesulfonamide [no description available]	2.15	1	nitro compound; quinolines
1-(4-methoxyphenyl)-N-(4-methyl-2-pyridinyl)-5-oxo-3-pyrrolidinecarboxamide [no description available]	2.15	1	pyrrolidines
3,4,5-trimethoxy-N-[4-[(2-methyl-1-piperidinyl)sulfonyl]phenyl]benzamide [no description available]	2.15	1	benzamides
3-(n,n-dimethylsulfonamido)-4-methyl-nitrobenzene BRL-50481 : A C-nitro compound that is benzene substituted by N,N-dimethylaminosulfonyl, methyl and nitro groups at positions 1, 2 and 5, respectively. It is a phosphodiesterase inhibitor selective for the PDE7 subtype (Ki = 180 nM).	2.15	1	C-nitro compound; sulfonamide; toluenes	bone density conservation agent; EC 3.1.4.53 (3',5'-cyclic-AMP phosphodiesterase) inhibitor; geroprotector
6,3',4'-Trimethoxyflavanone [no description available]	2.15	1	ether; flavonoids
1-[4-(3-ethoxyphenoxy)butyl]imidazole [no description available]	2.15	1	aromatic ether
5-[[(1-cyclohexyl-5-tetrazolyl)thio]methyl]-3-phenyl-1,2,4-oxadiazole [no description available]	2.15	1	oxadiazole; ring assembly
2-[1-(3,4-dihydro-2H-quinolin-1-yl)-1-oxopropan-2-yl]isoindole-1,3-dione [no description available]	2.15	1	phthalimides
[4-(benzenesulfonyl)-1-piperazinyl]-(1-piperidinyl)methanone [no description available]	2.15	1	sulfonamide
3-(2,5-dioxo-1-pyrrolidinyl)-N-(2-methyl-1,3-dioxo-5-isoindolyl)benzamide [no description available]	2.15	1	amidobenzoic acid
6-[[[5-(ethylthio)-1,3,4-thiadiazol-2-yl]amino]-oxomethyl]-1-cyclohex-3-enecarboxylic acid [no description available]	2.15	1	aromatic amide
2,5-dimethoxy-n-(quinolin-3-yl)benzenesulfonamide 2,5-dimethoxy-N-(quinolin-3-yl)benzenesulfonamide: a tissue-nonspecific alkaline phosphatase inhibitor; structure in first source	2.15	1	quinolines
LSM-25805 [no description available]	2.15	1	isoindoles
4-ethoxy-N-(3-quinolinyl)benzenesulfonamide [no description available]	2.15	1	quinolines
3-chloro-N-[3-(1-imidazolyl)propyl]-6-nitro-1-benzothiophene-2-carboxamide [no description available]	2.15	1	1-benzothiophenes
nsc 727447 NSC 727447: structure in first source	2.15	1
2-methoxy-N-[(4-methylphenyl)methyl]-2-phenylacetamide [no description available]	2.15	1	acetamides
2-(4-chlorophenoxy)-N-(5-nitro-2-thiazolyl)acetamide [no description available]	2.15	1	C-nitro compound; thiazoles
7-(2-methoxyphenyl)-5-phenyl-1,7-dihydrotetrazolo[1,5-a]pyrimidine [no description available]	2.15	1	methoxybenzenes
N-[3-[2,5-dioxo-3-(phenylmethyl)-1-pyrrolidinyl]phenyl]acetamide [no description available]	2.15	1	pyrrolidines
3,4-dimethoxy-N-[3-(methylthio)phenyl]benzenesulfonamide [no description available]	2.15	1	sulfonamide
3-methyl-4-nitro-N-(1H-1,2,4-triazol-5-yl)benzamide [no description available]	2.15	1	C-nitro compound
2-[(4-chlorophenyl)methylthio]-N-(2-hydroxy-5-nitrophenyl)acetamide [no description available]	2.15	1	nitrophenol
2-(4-ethoxyphenyl)-N-[3-(1-imidazolyl)propyl]-4-quinolinecarboxamide [no description available]	2.15	1	quinolines
N-(4-bromophenyl)-5-methyl-4-nitro-1H-pyrazol-3-amine [no description available]	2.15	1	C-nitro compound
3,3-bis(4-hydroxyphenyl)-7-methyl-1,3-dihydro-2h-indol-2-one 3,3-bis(4-hydroxyphenyl)-7-methyl-1,3-dihydro-2H-indol-2-one: an estrogen receptor alpha inhibitor	2.15	1
N-[4-[(cyclohexylamino)-oxomethyl]phenyl]-3-pyridinecarboxamide [no description available]	2.15	1	aromatic amide
N,N,4-trimethyl-2-[[(5-methyl-2-furanyl)-oxomethyl]amino]-5-thiazolecarboxamide [no description available]	2.15	1	aromatic amide; thiazoles
ex 527 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide: structure in first source. 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide : A member of the class of carbazoles that is 2,3,4,9-tetrahydro-1H-carbazole which is substituted at position 1 by an aminocarbohyl group and at position 6 by a chlorine.	2.15	1	carbazoles; monocarboxylic acid amide; organochlorine compound
3-[3-[(5-ethyl-[1,2,4]triazino[5,6-b]indol-3-yl)thio]propyl]-1H-benzimidazol-2-one [no description available]	2.15	1	indoles
4-methyl-2,7-diphenyl-8H-pyrido[2,3-d]pyrimidin-5-one [no description available]	2.15	1	phenylpyridine
3-methylharman [no description available]	2.15	1
aluminum Aluminum: A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.	3.15	5	boron group element atom; elemental aluminium; metal atom
arsenic Arsenic: A shiny gray element with atomic symbol As, atomic number 33, and atomic weight 75. It occurs throughout the universe, mostly in the form of metallic arsenides. Most forms are toxic. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), arsenic and certain arsenic compounds have been listed as known carcinogens. (From Merck Index, 11th ed)	2.07	1	metalloid atom; pnictogen	micronutrient
1-methyl-beta-carboline-3-carboxylic acid 1-methyl-beta-carboline-3-carboxylic acid: metabolite from cows fed with corn silage; structure in first source	2.15	1
gadolinium dtpa Gadolinium DTPA: A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)	1.99	1	gadolinium coordination entity	MRI contrast agent
chiniofon Hydroxyquinolines: The 8-hydroxy derivatives inhibit various enzymes and their halogenated derivatives, though neurotoxic, are used as topical anti-infective agents, among other uses.	3.88	12
sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.	2.15	1	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
2-methyl-4(3h)-quinazolinone 2-methyl-4(3H)-quinazolinone: from Bacillus cereus; structure given in first source	2.15	1
n(4)-desoxychlordiazepoxide N(4)-desoxychlordiazepoxide: not phototoxic; structure given in first source	2.15	1
2-amino-3-hydroxyphenazine 2-amino-3-hydroxyphenazine: structure given in first source	2.15	1
2-styrylquinazolin-4(3h)-one 2-styrylquinazolin-4(3H)-one: structure given in first source	2.15	1
2-amino-5-iodo-6-phenyl-4-pyrimidinone [no description available]	2.15	1
quininib quininib: has antiangiogenic activity; structure in first source. quininib : A styrylquinoline that is trans-2-styrylquinoline in which the the phenyl group has been substituted at position 2 by a hydroxy group. It is an anti-angiogenic compound that exerts a dose-dependent antagonism of the cysteinyl leukotriene pathway, preferentially antagonising cysteinyl leukotriene receptor 1. The major species at pH 7.3	2.15	1	phenols; styrylquinoline	angiogenesis inhibitor
bropirimine [no description available]	2.15	1	pyrimidines
2-[(6-ethyl-4-methyl-2-quinazolinyl)amino]-1H-quinazolin-4-one [no description available]	2.15	1	quinazolines
2-[(6-ethyl-4-methyl-2-quinazolinyl)amino]-6-(methoxymethyl)-1H-pyrimidin-4-one [no description available]	2.15	1	quinazolines

Condition	Relationship Strength	Studies
Plasmodium falciparum Malaria [description not available]	2.1	1
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	2.1	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.55	2
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Retinal Degeneration A retrogressive pathological change in the retina, focal or generalized, caused by genetic defects, inflammation, trauma, vascular disease, or aging. Degeneration affecting predominantly the macula lutea of the retina is MACULAR DEGENERATION. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p304)	2.1	1
Abscess, Amebic, Hepatic [description not available]	1.95	1

8-hydroxy-7-iodo-5-quinolinesulfonic acid

Description

Cross-References

Synonyms (74)

Research Excerpts

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (15)

Potency Measurements

Inhibition Measurements

Bioassays (39)

Research

Studies (27)

Market Indicators

Research Demand Index: 19.55

Study Types

8-hydroxy-7-iodo-5-quinolinesulfonic acid

Description

Cross-References

Synonyms (74)

Research Excerpts

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (15)

Potency Measurements

Inhibition Measurements

Bioassays (39)

Research

Studies (27)

Market Indicators

Research Demand Index: 19.55

Study Types

Related Drugs (571)

Related Conditions (9)